Samsung Biologics has secured a record $1.41 billion contract with an unnamed European pharmaceutical company, the contract development and manufacturing organization (CDMO) announced in an electronic disclosure Tuesday.
Antibody-drug conjugates (ADCs) are a growing trend in cancer treatment, with recent breakthroughs attracting significant investment from pharmaceutical and biotech companies worldwide.
With the global life science industry’s eyes set on San Francisco, Korea’s emerging or rising biopharma companies gathered in the Bay area to join the annual J.P. Morgan Healthcare Conference.
Celltrion Holdings will go public, its founder and chairman Seo Jung-jin said, in a bid to establish a massive 100-trillion-won ($75.8-billion) healthcare fund.
SK Biopharmaceuticals expects positive cash flow from the epilepsy drug Xcopri, and aims for $2 billion in sales by 2029.
SAN FRANCISCO — After a record breaking 2023, Samsung Biologics expects both horizontal and vertical growth to continue into this year with upped capacity and expanded modalities.
Korean biopharma shines at J.P. Morgan Healthcare Conference amid global industry optimism.
Around 20 Korean biopharmaceutical companies are set to attend the 40th annual J.P. Morgan HealthCare Conference, which will be held online Jan. 10 to 13 and is often referred to as the bio shopping mall for investors around the world.
Korea JoongAng Daily Sitemap
